Stephen A Strickland Selected Research

vosaroxin

11/2018	Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
9/2016	Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
9/2015	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen A Strickland Research Topics

Disease

21	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2022 - 06/2010
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021 - 06/2010
3	Neoplasms (Cancer) 12/2021 - 09/2016
2	Acute Promyelocytic Leukemia 01/2021 - 01/2018
2	Leukemia 10/2018 - 09/2015
2	Febrile Neutropenia 09/2015 - 11/2012
2	Neutropenia 09/2015 - 11/2012
2	Pneumonia (Pneumonitis) 09/2015 - 11/2012
1	B-Cell Leukemia (Leukemia, B Cell) 01/2019
1	Lymphoma (Lymphomas) 01/2019
1	Myeloid Leukemia (Leukemia, Myelocytic) 12/2018
1	Fatigue 01/2017
1	Residual Neoplasm 03/2016
1	Sepsis (Septicemia) 09/2015
1	Stomatitis 09/2015
1	Thrombocytopenia (Thrombopenia) 11/2012

Drug/Important Bio-Agent (IBA)

9	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 09/2015
4	venetoclaxIBA 01/2021 - 12/2018
4	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2020 - 09/2015
3	vosaroxinIBA 11/2018 - 09/2015
2	CPX-351IBA 01/2020 - 10/2018
2	Pharmaceutical PreparationsIBA 10/2018 - 03/2013
2	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2018 - 09/2015
2	alvocidib (flavopiridol)IBA 01/2018 - 09/2015
2	Transfer RNA (tRNA)IBA 01/2017 - 09/2015
1	sapacitabineIBA 12/2021
1	selinexorIBA 12/2021
1	midostaurinIBA 12/2020
1	eltrombopag FDA Link 01/2020
1	Histone Deacetylase InhibitorsIBA 10/2019
1	PanobinostatIBA 10/2019
1	Proteins (Proteins, Gene)FDA Link 12/2018
1	Liposomes (Liposome)IBA 10/2018
1	Core Binding Factors (Core-Binding Factor)IBA 01/2018
1	Alanine Transaminase (SGPT)IBA 01/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	QuinolonesIBA 09/2016
1	DNA (Deoxyribonucleic Acid)IBA 09/2016
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 09/2016
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 01/2016
1	RNA (Ribonucleic Acid)IBA 09/2015
1	antineoplaston A10 (A 10)IBA 11/2012

Therapy/Procedure

7	Therapeutics 03/2022 - 09/2015
4	Drug Therapy (Chemotherapy) 12/2020 - 10/2018
2	Cell Transplantation 01/2020 - 01/2020
1	Induction Chemotherapy 12/2021
1	Blood Transfusion (Blood Transfusions) 01/2021
1	Off-Label Use 01/2020
1	Salvage Therapy 01/2020
1	Consolidation Chemotherapy 01/2020
1	Stem Cell Transplantation 06/2010